A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in Combination With a Surgical Lymph Node Transfer for the Treatment of Patients With Secondary Lymphedema

Trial Profile

A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in Combination With a Surgical Lymph Node Transfer for the Treatment of Patients With Secondary Lymphedema

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs AdVEGF-Herantis (Primary)
  • Indications Breast cancer; Lymphoedema
  • Focus Adverse reactions; First in man
  • Sponsors Herantis Pharma
  • Most Recent Events

    • 29 Aug 2017 According to a Herantis Pharma media release, this trial advanced in March to the highest dose and in June to the last patient cohort.
    • 22 Jun 2017 According to a Herantis Pharma media release, after assessing safety data on all treated patients, including the first patients treated with the highest dose the study's Data Monitoring Committee of independent experts recommended proceeding with the study as planned. The study centers can proceed to recruit patients at their own pace on the high dose level.
    • 30 May 2017 Planned number of patients changed from 18 to 21.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top